Clinical Trial Detail

NCT ID NCT04239157
Title Canakinumab and Azacitidine for the Treatment of Low or Intermediate Risk Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

chronic myelomonocytic leukemia

myelodysplastic syndrome

Therapies

Azacitidine + Canakinumab

Age Groups: adult senior

No variant requirements are available.